ImPact Biotech
Targeted Treatment for Selective Tumor Ablation
Active
Pre-Funding
Startup
Ness Ziona
Founded 1996-01
ImPact Biotech is focused on the development and launch of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a targeted treatment for selective tumor ablation. Padeliporfin VTP therapy is a novel Oncology technology platform that comprises the intravenous delivery of an inactive drug, Padeliporfin, which is then precisely activated only in the tumo…
SectorHealth Tech & Life Sciences
StagePre-Funding
Total raised$2.7M
Employees40
Founded1996-01
HQNess Ziona
Patents1
Confidence80
Sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technology
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals